Dyne Therapeutics (NASDAQ:DYN) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a strong sell rating to a sell rating in a research report released on Monday morning.

Several other equities research analysts have also recently commented on DYN. Chardan Capital reissued a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. TD Cowen began coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Dyne Therapeutics Stock Down 0.2%

NASDAQ DYN opened at $22.80 on Monday. Dyne Therapeutics has a 1-year low of $8.24 and a 1-year high of $25.00. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of -7.10 and a beta of 1.06. The stock’s 50 day moving average is $18.78 and its two-hundred day moving average is $18.21. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) EPS. Equities analysts forecast that Dyne Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 309,268 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $21.28, for a total value of $6,581,223.04. Following the sale, the director owned 1,016,633 shares of the company’s stock, valued at $21,633,950.24. The trade was a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have acquired 9,000 shares of company stock worth $156,800 and have sold 2,334,279 shares worth $46,221,906. Company insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently added to or reduced their stakes in DYN. T. Rowe Price Investment Management Inc. grew its stake in shares of Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares in the last quarter. Vanguard Group Inc. increased its stake in Dyne Therapeutics by 14.9% during the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after acquiring an additional 1,455,151 shares during the last quarter. State Street Corp raised its position in Dyne Therapeutics by 27.0% during the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after purchasing an additional 1,423,828 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Dyne Therapeutics by 45.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after purchasing an additional 1,618,000 shares during the period. Finally, Orbis Allan Gray Ltd bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at approximately $93,926,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.